title: [The inhibitory action of the antisense oligodeoxynucleotide to the expression of vascular endothelial growth factor by radiotherapy in a prostate cancer cell line].
abstract: OBJECTIVE
  To investigate mechanism for the increasing level of serum vascular endothelial growth factor(VEGF) in tumour patients during radiotherapy and the inhibitory action of the antisense oligodeoxynucleotide (AS-ODN) to the expression of VEGF protein by radiotherapy in the prostate cancer cell line (PC3M).
  
  
  METHODS
  To observe the changes of serum VEGF in the prostate cancer patients during radiotherapy dynamically and the inhibitory action of the antisense oligodeoxynucleotide to the expression of VEGF by radiotherapy in PC3M.
  
  
  RESULTS
  The changes of serum VEGF in three patients receiving radiotherapy had been observed continuously. The levels of serum VEGF began to increase when the patients received radiotherapy and rised up to peak value after fifteen days, then declined to the range of pre-radiotherapy. Irradiating the PC3M cells with X-rays significantly increased the VEGF expression and secretion. The expression of VEGF protein in the group treated by VEGF AS-ODNs and X-ray irradiation decreased significantly than the group treated only by X-ray irradiation.
  
  
  CONCLUSIONS
  The induction of VEGF protein expression by X-ray irradiation in tumor cells may result in the increasing of the VEGF in the prostate cancer patients during radiotherapy and the induction can be blocked by VEGF AS-ODNs.
authors.affiliation: Clinical Laboratory, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110015, China.
authors.forename: Dong-Ya
authors.initials: DY
authors.lastname: Meng
authors.forename: Wen-Cheng
authors.initials: WC
authors.lastname: Xue
authors.forename: Xiao-Fang
authors.initials: XF
authors.lastname: Hu
authors.forename: Yi-Nan
authors.initials: YN
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Luo
mesh_terms: D016373:DNA, Antisense / Q000494:pharmacology*; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors* / Q000097:blood / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects* / Q000528:radiation effects; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood / Q000235:genetics; D008222:Lymphokines / Q000037:antagonists & inhibitors* / Q000097:blood / Q000235:genetics; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D011878:Radiotherapy / Q000009:adverse effects; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016373:DNA, Antisense; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors